The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Biochemical Evidence for Impaired Nitric Oxide Synthesis in Patients With Peripheral Arterial Occlusive Disease
Abstract
Background We studied urinary nitrate and cGMP excretion rates, indices of systemic NO formation, and plasma concentrations of l -arginine and the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) and its inactive stereoisomer, symmetrical dimethylarginine, in 77 patients with peripheral arterial occlusive disease (PAOD) in Fontaine stages IIb through IV and in 47 young and 37 elderly healthy control subjects. Methods and Results Urinary nitrate excretion was 182.0±11.4 μmol/mmol creatinine and cGMP excretion was 186.2±13.0 nmol/mmol creatinine in young healthy control subjects. In elderly control subjects, both excretion rates were slightly lower (nitrate, 156.0±7.8 μmol/mmol creatinine; cGMP, 150.0±8.3 nmol/mmol creatinine; P =NS). In PAOD patients, there was a significant, progressive reduction of urinary nitrate (IIb, 138.4±11.9; III, 128.6±11.3; and IV, 91.9±8.0 μmol/mmol creatinine; P <.05) and cGMP (IIb, 139.9±25.2; III, 115.6±13.1; and IV, 76.9±7.9 nmol/mmol creatinine; P <.05) excretion rates related to the Fontaine stage of PAOD. These changes were independent of changes in renal excretory function. Plasma l -arginine concentrations were not significantly different between the groups, but ADMA concentrations were elevated in PAOD patients (young control subjects, 1.25±0.11; elderly control subjects, 1.01±0.05 μmol/L; IIb, 2.62±0.24; III, 3.06±0.48; and IV, 3.49±0.26 μmol/L; P <.05 for PAOD versus control subjects). There was a significant linear correlation between urinary nitrate and cGMP excretion rates and a significant negative linear correlation between plasma ADMA concentrations and urinary nitrate excretion. Conclusions In PAOD patients, there is a progressive reduction in urinary nitrate and cGMP excretion rates, which may be caused in part by accumulation of ADMA, an endogenous inhibitor of NO synthase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Nitric oxide: an endogenous modulator of leukocyte adhesion.
Kubes, P., Suzuki, M., & Granger, D. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4651 · Cited by 3,029
Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary Arteries
Ludmer, P. L., Selwyn, A. P., Shook, T. L., Wayne, R. R., Mudge, G. H., Alexander, R. W., & Ganz, P. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610233151702 · Cited by 2,425
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
Hypercholesterolemia increases endothelial superoxide anion production.
Ohara, Y., Peterson, T. E., & Harrison, D. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116491 · Cited by 1,765
Biosynthesis and Metabolism of Endothelium-Derived Nitric Oxide
Ignarro, L. J. (1990) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.30.040190.002535 · Cited by 1,314
Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.
Förstermann, U., Closs, E. I., Pollock, J. S., Nakane, M., Schwarz, P., Gath, I., & Kleinert, H. (1994) · Hypertension · doi:10.1161/01.hyp.23.6.1121 · Cited by 1,111
Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.
Creager, M. A., Cooke, J. P., Mendelsohn, M. E., Gallagher, S. J., Coleman, S. M., Loscalzo, J., & Dzau, V. J. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114688 · Cited by 1,017
Pollock, J. S., Förstermann, U., Mitchell, J. A., Warner, T. D., Schmidt, H. H., Nakane, M., & Murad, F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10480 · Cited by 980
L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.
Creager, M. A., Gallagher, S. J., Girerd, X. J., Coleman, S. M., Dzau, V. J., & Cooke, J. P. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115987 · Cited by 813
Cited by
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.
Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., Kearney, M., Chen, D., Symes, J. F., Fishman, M. C., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1560 · Cited by 1,200
Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Self-citationZoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07217-8 · Cited by 1,087
Cellular and molecular mechanisms of endothelial cell dysfunction.
Harrison, D. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119751 · Cited by 1,053
Endogenous Nitric Oxide Synthase Inhibitor: A Novel Marker of Atherosclerosis
Miyazaki, H., Matsuoka, H., Cooke, J. P., Usui, M., Ueda, S., Okuda, S., & Imaizumi, T. (1999) · Circulation · doi:10.1161/01.cir.99.9.1141 · Cited by 756
Ito, A., Tsao, P. S., Adimoolam, S., Kimoto, M., Ogawa, T., & Cooke, J. P. (1999) · Circulation · doi:10.1161/01.cir.99.24.3092 · Cited by 631
Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor
Stühlinger, M. C. (2002) · JAMA · doi:10.1001/jama.287.11.1420 · Cited by 581
Does ADMA Cause Endothelial Dysfunction?
Cooke, J. P. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.9.2032 · Cited by 581
The role of nitric oxide in cardiovascular diseases
NASEEM, K. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.09.003 · Cited by 557
Lüscher, T. F., & Barton, M. (1997) · Clinical Cardiology · doi:10.1002/j.1932-8737.1997.tb00006.x · Cited by 536
Böger, R. H., Sydow, K., Borlak, J., Thum, T., Lenzen, H., Schubert, B., Tsikas, D., & Bode-Böger, S. M. (2000) · Circulation Research · doi:10.1161/01.res.87.2.99 · Cited by 479
Self-citationSydow, K., & Münzel, T. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00033-3 · Cited by 433
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Sibal, L., C Agarwal, S., D Home, P., & H Boger, R. (2010) · Current Cardiology Reviews · doi:10.2174/157340310791162659 · Cited by 433
Surdacki, A., Nowicki, M., Sandmann, J., Tsikas, D., Boeger, R. H., Bode-Boeger, S. M., Kruszelnicka-Kwiatkowska, O., Kokot, F., Dubiel, J. S., & Froelich, J. C. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199904000-00020 · Cited by 426
Teerlink, T., Nijveldt, R. J., de Jong, S., & van Leeuwen, P. A. M. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5575 · Cited by 417
Kielstein, J. T., Impraim, B., Simmel, S., Bode-Böger, S. M., Tsikas, D., Frölich, J. C., Hoeper, M. M., Haller, H., & Fliser, D. (2004) · Circulation · doi:10.1161/01.cir.0000105764.22626.b1 · Cited by 401
Self-citationAsymmetrical Dimethylarginine: The Über Marker?
Cooke, J. P. (2004) · Circulation · doi:10.1161/01.cir.0000126823.07732.d5 · Cited by 396
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
BOGER, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00500-5 · Cited by 393
Self-citationSchnabel, R., Blankenberg, S., Lubos, E., Lackner, K. J., Rupprecht, H. J., Espinola-Klein, C., Jachmann, N., Post, F., Peetz, D., Bickel, C., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000181286.44222.61 · Cited by 378
Kielstein, J. T., Bo[Combining Diaeresis]ger, R. H., Bode-Bo[Combining Diaeresis]ger, S. M., Fro[Combining Diaeresis]lich, J. D. C., Haller, H., Ritz, E., & Fliser, D. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v131170 · Cited by 369
Böger, R. H. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.10.2842s · Cited by 363
Self-citationKIELSTEIN, J. T., BÖGER, R. H., BODE-BÖGER, S. M., SCHÄFFER, J., BARBEY, M., KOCH, K. M., & FRÖLICH, J. C. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103594 · Cited by 361
The l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio
BODEBOGER, S., SCALERA, F., & IGNARRO, L. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.002 · Cited by 347
The Clinical Pharmacology of L-Arginine
Böger, R. H., & Bode-Böger, S. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.79 · Cited by 331
Role of Endothelial Nitric Oxide Synthase in Endothelial Cell Migration
Murohara, T., Witzenbichler, B., Spyridopoulos, I., Asahara, T., Ding, B., Sullivan, A., Losordo, D. W., & Isner, J. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1156 · Cited by 320
l -Arginine improves the symptoms of strokelike episodes in MELAS
Koga, Y., Akita, Y., Nishioka, J., Yatsuga, S., Povalko, N., Tanabe, Y., Fujimoto, S., & Matsuishi, T. (2005) · Neurology · doi:10.1212/01.wnl.0000151976.60624.01 · Cited by 312
Arginine Nutrition and Cardiovascular Function
Wu, G., & Meininger, C. J. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.11.2626 · Cited by 286
De Bree, A., Verschuren, W. M. M., Kromhout, D., Kluijtmans, L. A. J., & Blom, H. J. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.599 · Cited by 282
Böger, R. H., Bode-Böger, S. M., Sydow, K., Heistad, D. D., & Lentz, S. R. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1557 · Cited by 278
Self-citationKlotho Protein Protects against Endothelial Dysfunction
Saito, Y., Yamagishi, T., Nakamura, T., Ohyama, Y., Aizawa, H., Suga, T., Matsumura, Y., Masuda, H., Kurabayashi, M., Kuro-o, M., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8943 · Cited by 274
Asymmetric Dimethylarginine, L-Arginine, and Endothelial Dysfunction in Essential Hypertension
Perticone, F., Sciacqua, A., Maio, R., Perticone, M., Maas, R., Boger, R. H., Tripepi, G., Sesti, G., & Zoccali, C. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.040 · Cited by 271
Self-citationDiabetes and Alpha Lipoic Acid
Golbidi, S., Badran, M., & Laher, I. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00069 · Cited by 270
Böger, R. H., Bode-Böger, S. M., Thiele, W., Creutzig, A., Alexander, K., & Frölich, J. C. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00375-1 · Cited by 264
Self-citationThe role of asymmetric and symmetric dimethylarginines in renal disease
Schwedhelm, E., & Böger, R. H. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.31 · Cited by 260
L‐arginine‐induced vasodilation in healthy humans:pharmacokinetic–pharmacodynamic relationship
Bode‐Böger, S. M., Böger, R. H., Galland, A., Tsikas, D., & Frölich, J. C. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00803.x · Cited by 259
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
Tain, Y., & Hsu, C. (2017) · Toxins · doi:10.3390/toxins9030092 · Cited by 258
Arginine and Endothelial Function
Gambardella, J., Khondkar, W., Morelli, M. B., Wang, X., Santulli, G., & Trimarco, V. (2020) · Biomedicines · doi:10.3390/biomedicines8080277 · Cited by 253
Fujiwara, N., Osanai, T., Kamada, T., Katoh, T., Takahashi, K., & Okumura, K. (2000) · Circulation · doi:10.1161/01.cir.101.8.856 · Cited by 242
Endogenous nitric oxide synthase inhibitors are responsible for the L‐arginine paradox
Tsikas, D., Böger, R. H., Sandmann, J., Bode-Böger, S. M., & Frölich, J. C. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01686-0 · Cited by 237
Self-citationIncreased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure
Usui, M., Matsuoka, H., Miyazaki, H., Ueda, S., Okuda, S., & Imaizumi, T. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00225-2 · Cited by 232
N., C., & J., C. (2002) · Diabetologia · doi:10.1007/s00125-002-0975-6 · Cited by 116
Davis, J. S., & Anstey, N. M. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181ffd9f7 · Cited by 86
l-Arginine transporters in cardiovascular disease: A novel therapeutic target
Chin-Dusting, J. P. F., Willems, L., & Kaye, D. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.001 · Cited by 69
Böger, R. H., Maas, R., Schulze, F., & Schwedhelm, E. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.196 · Cited by 65
Self-citationNitric Oxide: Implications for Vascular and Endovascular Surgery
Vural, K. M., & Bayazit, M. (2001) · European Journal of Vascular and Endovascular Surgery · doi:10.1053/ejvs.2001.1448 · Cited by 43
Rufa, A., Blardi, P., De Lalla, A., Cevenini, G., De Stefano, N., Zicari, E., Auteri, A., Federico, A., & Dotti, M. T. (2008) · Cerebrovascular Diseases · doi:10.1159/000166840 · Cited by 31
Cui, R., Iso, H., Yamagishi, K., Tanigawa, T., Imano, H., Ohira, T., Kitamura, A., Sato, S., & Shimamoto, T. (2006) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000209818.36067.51 · Cited by 26
Metadata
- Authors
- Böger, R. H., Bode-Böger, S. M., Thiele, W., Junker, W., Alexander, K., & Frölich, J. C.
- Venue
- Circulation
- Published
- 1997-04-15
- Volume
- 95
- Issue
- 8
- Pages
- 2068-2074
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1971061508
- Cited by
- 490
- References
- 37
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.